Results 151 to 160 of about 12,338 (219)

Intracellular glutathione determines bortezomib cytotoxicity in multiple myeloma cells

, 2016
Multiple myeloma (myeloma in short) is an incurable cancer of antibody-producing plasma cells that comprise 13% of all hematological malignancies.
Buene, Glenn, Holien, Toril, Johansson, Ida, Bjørkøy, Geir, Misund, Kristine, Waage, Anders, Starheim, Kristian Kobbenes, Baranowska, Katarzyna Anna, Hella, Hanne, Sundan, Anders, Sponaas, Anne Marit   +10 more
core  

Vacuolization as a Novel Approach to Cancer Therapy

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 6, June 2026.
This review discusses the novel strategy of inducing vacuole formation in cancer cells using small molecules, that induce nonapoptotic cell death mechanisms, such as paraptosis, oncosis, autophagy, and methuosis, and its potential in overcoming resistance to apoptosis‐based cancer therapies.
Mariah Pasternak, Noor Hussein, Veronica Piedra, Saloni Malla, Chandrabose Karthikeyan, Haneen Amawi, Harish Rajak, Charles R. Ashby Jr., R. Jayachandra Babu, Amit K. Tiwari   +9 more
wiley   +1 more source

RASGRP1 Deficiency Manifesting as Severe Vasculopathy and Fatal Autoimmune Hemolytic Anemia

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Background RASGRP1 deficiency is a rare inborn error of immunity characterized by immunodeficiency, autoimmunity, and lymphoproliferation. Results We report a 5‐year‐old male with novel homozygous splice‐donor mutations in RASGRP1(c.1720+1G>A and c.1720+2T>C) who presented with severe vasculopathy (ischemic stroke and thrombosis), secondary ...
Kosar Asna Ashari, Bahareh Yaghmaie, Neda Pak, Mohammad Shahrooei, Vahid Ziaee, Nima Parvaneh   +5 more
wiley   +1 more source

Precision Medicine in a Patient With Multiple Myeloma Presenting With t(2;11) and CCND1 Overexpression

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Translocations involving CCND1 are well described in multiple myeloma (MM), most frequently t(11;14), but rearrangements involving the immunoglobulin kappa (IGK) locus are rare. We present a case of a 71‐year‐old female with MM harboring t(2;11)(p11.2;q13), resulting in IGK::CCND1, with cyclin D1 and BCL‐2 overexpression.
Ariel Siegel, Chloe Ray, Meenakshi Mehrotra, Bruce Petersen, Sundar Jagannath, Samir Parekh, Jane Houldsworth, Hearn Jay Cho   +7 more
wiley   +1 more source

Triplet or Quadruplet Regimen Utilization and Overall Survival in Patients Diagnosed With Multiple Myeloma Between 2017 and 2023

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction Multiple myeloma treatment has rapidly evolved, but little is known about the uptake of guideline‐recommended triplet or quadruplet therapy in clinical practice. Methods This retrospective cohort study included adult patients newly diagnosed with multiple myeloma between January 1, 2017, and December 31, 2023, in one health system
Emily R. Wesley, Faiz Anwer, Michael B. Rothberg, Jeffrey D. Kovach, Nicholas J. Casacchia, Brittany Peterre, Ming Wang, Shahzad Raza, Louis S. Williams, Jason Valent, Hamlet Gasoyan   +10 more
wiley   +1 more source

Biological Drivers of IMiD‐Induced Peripheral Neuropathy in Multiple Myeloma

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT The introduction of immunomodulatory drugs (IMiDs), such as thalidomide, lenalidomide and pomalidomide, have led to significant improvements in multiple myeloma (MM) treatment. Many patients now live 10 years or longer with their disease, making treatment‐related side effects increasingly important.
Sina A. Beer, Richard Houlston, Martin F. Kaiser   +2 more
wiley   +1 more source

Real‐World Outcomes of Thromboprophylaxis With Apixaban in Patients With Newly Diagnosed Multiple Myeloma, the MyelMeXa Study

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Background Multiple myeloma (MM) carries a high venous thromboembolism (VTE) risk; aspirin shows limited efficacy, while factor‐Xa inhibitors show promise. Objectives Evaluate apixaban for primary thromboprophylaxis in newly diagnosed MM (NDMM).
K. Alexandra Sanchez, Gabriela Cesarman‐Maus, Michelle Flores‐Cruz, Beatriz Cabello, Ramiro Espinoza, Omar Eduardo Fernandez‐Vargas   +5 more
wiley   +1 more source

Therapeutic Options for IgA Pemphigus in Patients Refractory to Dapsone

JEADV Clinical Practice, Volume 5, Issue 2, Page 415-424, June 2026.
ABSTRACT IgA pemphigus is a rare autoimmune blistering disorder with limited therapeutic guidance available due to its rarity and complex presentation. This comprehensive analysis evaluates the therapeutic outcomes of 67 published patients, emphasising the significant role of dapsone as the first‐line treatment.
Lorenz Frasheri, Marta Dechant, Tilo Biedermann   +2 more
wiley   +1 more source

Hepatic Monoclonal Light‐ and Heavy‐Chain Deposition Disease Presenting as Noncirrhotic Portal Hypertension With Ascites

Liver International Communications, Volume 7, Issue 2, June 2026.
ABSTRACT Monoclonal immunoglobulin deposition disease (MIDD) is a plasma cell disorder where immunoglobulin light‐ and/or heavy‐chains accumulate in various organs. Hepatic involvement can be challenging to diagnose, as manifestations are protean and Congo red staining is negative.
Bella L. Liu, Helmut G. Rennke, Lei Zhao, Kayla R. Elliott, Yuxin Liu, Stephen D. Zucker   +5 more
wiley   +1 more source

Fatty Acid Metabolism in Health and Cancer: From Fundamental Mechanisms to Therapeutic Application

MedComm, Volume 7, Issue 6, June 2026.
The modulation of the TME by fatty acid metabolism primarily occurs through four key pathways: inflammation regulation, signal transduction, translation to TME, and oxidative stress. ABSTRACT Fatty acid metabolism (FAM) plays a vital role in maintaining health by supporting energy production, cellular structure, and signaling processes.
Na Hang, Runkang Zhao, Fan Zhang, Dandan Guo, Qing Li, Zhijun Shen, Ruiqing Gao, Chenyu Gao, Zhao Xie, Sentao Fu, Peng Luo, Bufu Tang, Ling Wang   +12 more
wiley   +1 more source